NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

NCT04175262

CompletedN/A

Sponsor: Pfizer

Conditions: Metastatic Renal Cell Carcinoma (mRCC)

Interventions: sunitinib

Countries: Canada

The study aims to assess clinical outcomes in mRCC patients treated with sunitinib in second-line following IO therapy in real world clinical practices.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

  * Diagnosed with mRCC
  * Received IO therapy as 1L therapy
  * Received sunitinib as 2L therapy
  * Age 18 years or over at the time of mRCC diagnosis
  * Actively treated at an IMDC clinical center (to avoid incomplete data)

Exclusion Criteria:

None

Locations (1)

Calgary, Alberta, Canada